# A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma

> **NCT02706782** · PHASE1 · UNKNOWN · sponsor: **Shanghai GeneChem Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** TAI-meso-CART

## Key facts

- **NCT ID:** NCT02706782
- **Lead sponsor:** Shanghai GeneChem Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2018-02
- **Final completion:** 2018-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706782, "A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02706782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*